Clinical relevance of measurement of brain natriuretic peptide and N-terminal pro-brain natriuretic peptide in pediatric cardiology

Clinica Chimica Acta

Volumn 390, Issue 1-2, 2008, Pages 12-22

  Cantinotti, Massimiliano ^a   Clerico, Aldo ^a,b   Murzi, Michele ^a   Vittorini, Simona ^a   Emdin, Michele ^a  

^a INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^b SCUOLA SUPERIORE SANT ANNA   (Italy)

Author keywords

BNP; Cardiac natriuretic hormones; Diagnostic accuracy; Evidence based laboratory medicine; NT proBNP; Pediatric cardiology

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANTHRACYCLINE DERIVATIVE; BRAIN NATRIURETIC PEPTIDE;

ADULT; AGED; CHILD; COMPUTER ANALYSIS; CONGENITAL HEART DISEASE; CONTROLLED STUDY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DISEASE MARKER; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEART FAILURE; HEART VENTRICLE OVERLOAD; HUMAN; MALE; PEDIATRIC CARDIOLOGY; PEPTIDE ANALYSIS; PRIORITY JOURNAL; REFERENCE VALUE; REVIEW;

CARDIOLOGY; CHILD; HEART DISEASES; HUMANS; NATRIURETIC PEPTIDE, BRAIN; PEDIATRICS; PROTEIN PRECURSORS;

EID: 39649092936     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2007.12.020     Document Type: Review

References (126)

1. Rosenthal D., Chrisant M., Edens E., Mahony L., Canter C., Colan S., et al. International Society of Heart and Lung Transplantation: practice guidelines for management of heart failure in children. J Heart Lung Transpl 23 (2004) 1313-1333
2. Clerico A., Recchia F.A., Passino C., and Emdin M. Cardiac endocrine function is an essential component of the homeostatic regulation network: physiological and clinical implications. (Review). Am J Physiol Heart Circ Physiol 290 (2006) 17-29
3. Clerico A., Fontana M., Zyw L., Passino C., and Emdin M. Comparison of the diagnostic accuracy of Brain Natriuretic Peptide (BNP) and the N-terminal part of the propeptide of BNP immunoassays in chronic and acute heart failure: a systematic review. Clin Chem 53 (2007) 813-822
4. Clerico A., and Emdin M. Diagnostic accuracy and prognostic relevance of the measurement of the cardiac natriuretic peptides: a review. (Review). Clin Chem 50 (2004) 33-50
5. Doust J.A., Glasziou P.P., Pietrzak E., and Dobson A.J. A systematic review of the diagnostic accuracy of natriuretic peptides for heart failure. (Review). Arch Intern Med 164 (2004) 1978-1984
6. Nieminen M.S., Bohm M., Cowie M.R., Drexler H., Filippatos G.S., Jondeau G., et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the task force on acute heart failure of the European society of cardiology. Eur Heart J 26 (2005) 384-416
7. Swedberg K., Cleland J., Dargie H., Drexler H., Follath F., Komajda M., et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology. Eur Heart J 26 (2005) 1115-1140
8. Cameron V.A., and Ellmers L.J. Minireview: natriuretic peptides during development of the fetal heart and circulation. Endocrinology 144 (2003) 2191-2194
9. Cheung C.Y. Regulation of atrial natriuretic factor secretion and expression in the ovine fetus. Neurosci Biobehav Rev 19 (1995) 159-164
10. Deloof S., and Chatelain A. Effect of blood volume expansion on basal plasma atrial natriuretic factor and adrenocorticotropic hormone secretions in the fetal rat at term. Biol Neonate 65 (1994) 390-395
11. Johnson D.D., Singh M.B., and Cheung C.Y. Effect of three hours of hypoxia on atrial natriuretic factor gene expression in the ovine fetal heart. Am J Obstet Gynecol 176 (1997) 42-48
12. Rosenfeld C.R., Samson W.K., Roy T.A., Faucher D.J., and Magness R.R. Vasoconstrictor-induced secretion of ANP in fetal sheep. Am J Physiol 263 (1992) 526-533
13. Wei Y.F., Rodi C.P., Day M.L., Wiegand R.C., Needleman L.D., Cole B.R., et al. Developmental changes in the rat atriopeptin hormonal system. J Clin Invest 79 (1987) 1325-1329
14. Cheung C.Y. Regulation of atrial natriuretic factor release by endothelin in ovine fetuses. Am J Physiol 267 (1994) 380-386
15. Abell T.J., Richards A.M., Ikram H., Espiner E.A., and Yandle T. Atrial natriuretic factor inhibits proliferation of vascular smooth muscle cells stimulated by platelet-derived growth factor. Biochem Biophys Res Commun 160 (1989) 1392-1396
16. Horio T., Nishikimi T., Yoshihara F., Matsuo H., Takishita S., and Kangawa K. Inhibitory regulation of hypertrophy by endogenous atrial natriuretic peptide in cultured cardiac myocytes. Hypertension 35 (2000) 19-24
17. Wu C., Bishopric N., and Pratt R. Atrial natriuretic peptide induces apoptosis in neonatal rat cardiac myocytes. J Biol Chem 272 (1997) 14860-14866
18. Cao L., and Gardner D. Natriuretic peptides inhibit DNA synthesis in cardiac fibroblasts. Hypertension 25 (1995) 227-234
19. Clerico A., Del Ry S., Maffei S., Prontera C., Emdin M., and Giannessi D. The circulating levels of cardiac natriuretic hormones in healthy adults: effects of age and sex. Clin Chem Lab Med 40 (2002) 371-377
20. Redfield M.M., Rodeheffer R.J., Jacobsen S.J., et al. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 40 (2002) 976-982
21. Clerico A., Prontera C., Emdin M., Passino C., Storti S., Poletti R., et al. Analytical performance and diagnostic accuracy of immunometricassays for the measurement of plasma BNP and NT-proBNP concentrations. Clin Chem 51 (2005) 445-447
22. Panteghini M., and Clerico A. Understanding the clinical biochemistry of N-terminal pro-B-type natriuretic peptide: the prerequisite for its optimal clinical use. Clin Lab 50 (2004) 325-331
23. Apple F.S., Panteghini M., Ravkilde J., Mair J., Wu A.H.B., Tate J., et al. Behalf of the committee on standardization of markers of cardiac damage of the IFCC. Quality specifications for B-type natriuretic peptide assays. Clin Chem 51 (2005) 486-493
24. Emdin E., Clerico A., Clemenza F., Galvani M., Latini R., Masson S., et al. Consensus document. Recommendations for the clinical use of cardiac natriuretic peptides. Ital Heart J 6 (2005) 430-446
25. Mir T.S., Laux R., and Hellwege H.H. Plasma N-terminal proatrial-natriuretic peptide and plasma N-terminal-pro brain natriuretic peptide in healthy neonates: marked and rapid increase after birth. Pediatrics 112 (2003) 896-918
26. Koch A., and Singer H. Normal values of B type natriuretic peptide in infants, children, and adolescents. Heart 89 (2003) 875-878
27. Mir T.S., Flato M., Falkenberg J., Haddad M., Budden R., and Weil J. Plasma concentrations of N-terminal brain natriuretic peptide in healthy children, adolescents, and young adults: effect of age and gender. Pediatr Cardiol 27 (2006) 73-77
28. Rauh M., and Koch A. Plasma N-terminal natriuretic peptide concentration in control population of infants and children. Clin Chem 49 (2003) 1563-157l
29. Soldin S.J., Soldin O.P., Boyajian A.J., and Taskier M.S. Pediatric brain natriuretic peptide and N-terminal pro-brain natriuretic peptide reference intervals. Clin Chim Acta 366 (2006) 304-308
30. Yoshibayashi M., Kamiya T., Saito Y., Nakao K., Nishioka K., and Temma S. Plasma brain natriuretic peptide concentrations in healthy children from birth to adolescence: marked and rapid increase after birth. Eur J Endocrinol 133 (1995) 207-209
31. Nir A., Bar-Oz B., Perles Z., Brooks R., Korach A., and Rein A.J. N-terminal pro-B-type natriuretic peptide: reference plasma levels from birth to adolescence. Elevated levels at birth and in infants and children with heart diseases. Acta Paediatr 93 (2004) 603-607
32. Koch A.M., Rauh M., Zink S., and Singer M. Decreasing ratio of plasma N-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide according to age. Acta Paediatr 95 (2006) 805-809
33. Itoh H., Sagawa N., Hasegawa M., Okagaki A., Inamori K., Ihara Y., Mori T., et al. Brain natriuretic peptide levels in the umbilical venous plasma are elevated in fetal distress. Biol Neonate 64 (1993) 18-25
34. Bakker J., Gies I., Slavenburg B., Bekers O., Delhaas T., and Van Dieijen-Visser N. Reference values for N-terminal pro-B-type natriuretic peptide in umbilical cord blood. Clin Chem 50 (2004) 2465
35. Law Y.M., Keller B.B., Feingold B.M., and Boyle G.J. Usefulness of plasma B-type natriuretic peptide to identify ventricular dysfunction in pediatric and adult patients with congenital heart disease. Am J Cardiol 95 (2005) 474-478
36. Mir T.S., Marohn S., Laer S., Eiselt M., Grollmus O., and Weil J. Plasma concentrations of N-terminal pro-brain natriuretic peptide in control children from the neonatal to adolescent period and in children with congestive heart failure. Pediatrics 110 (2002) e76
37. Kunii Y., Kamada M., Ohtsuki S., Araki T., Kataoka K., and Kageyama M. Plasma brain natriuretic peptide and the evaluation of volume overload in infants and children with congenital heart disease. Acta Med Okayama 57 (2003) 191-197
38. Zhang W.L., and Du Z.D. Mean values of brain natriuretic peptide in 190 healthy children. Zhongguo Dang Dai Er Ke Za Zhi 8 (2006) 177-180
39. James N., and Smith M. Treatment of heart failure in children. Curr Paediatr 15 (2005) 539-548
40. Bettencourt P., Azevedo A., Pimenta J., Frioes F., Ferreira S., and Ferreira A. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation 110 (2004) 2168-2174
41. Mueller C., Scholer A., Laule-Kilian K., Martina B., Schindler C., Buser P., et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 350 (2004) 647-654
42. Doust J.A., Pietrzak E., Dobson A., and Glasziou P. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. Br Med J 330 (2005) 625
43. Daniels L.B., and Maisel A.S. Natriuretic peptides as diagnostic test: lessons from the first 5 years of clinical application. Heart Fail Clin 2 (2006) 299-309
44. Siebert U., Januzzi Jr. J.L., Beinfeld M.T., Cameron R., and Gazelle G.S. Cost-effectiveness of using N-terminal pro-brain natriuretic peptide to guide the diagnostic assessment and management of dyspneic patients in the emergency department. Am J Cardiol 98 (2006) 800-805
45. Troughton R.W., and Richards A.M. BNP for clinical monitoring of heart failure. Heart Fail Clin 2 (2006) 333-343
46. Morrison L.K., Harrison A., Krishnaswamy P., Kazanegra R., Clopto P., and Maisel A. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J Am Coll Cardiol 39 (2002) 202-209
47. Bolger A.P., Sharma R., Li W., Leenarts M., Kalra P.R., Kemp M., et al. Neurohumoral activation and the congenital heart failure syndrome in adults with congenital heart disease. Circulation 106 (2002) 92-99
48. Ohuchi H., Takasugi H., Ohashi H., Okada Y., Yamada O., Ono Y., et al. Stratification of pediatric heart failure on the basis of neurohormonal and cardiac autonomic nervous activities in patients with congenital heart disease. Circulation 108 (2003) 2368-2376
49. Price J.F., Thomas A.K., Grenier M., Eidem B.W., O'Brian Smith E., Denfield S.W., et al. B-type natriuretic peptide predicts adverse cardiovascular events in pediatric outpatients with chronic left ventricular systolic dysfunction. Circulation 114 (2006) 1063-1069
50. Wu Y.R., Chen S.B., Huang M.R., Zhang Y.Q., Sun K., and Chen S. Diagnostic value of plasma concentration of pro-brain natriuretic peptide in congestive heart failure in pediatric patients with ventricular septal defects. Zhonghua Er Ke Za Zhi 43 (2005) 161-164
51. Wu Y.R., Chen S.B., Sun K., Huang M.R., Zhang Y.Q., and Chen S. Diagnostic value of the currently used criteria and brain natriuretic peptide for diagnosing congestive heart failure in children with congenital heart disease. Zhonghua Er Ke Za Zhi 44 (2006) 728-732
52. Cohen S., Springer C., Avital A., Perles Z., Rein A.J., Argaman Z., et al. Amino-terminal pro-brain-type natriuretic peptide: heart or lung disease in pediatric respiratory distress?. Pediatrics 115 (2005) 1347-1350
53. Koulouri S., Acherman R.J., Wong P.C., Chan L.S., and Lewis A.B. Utility of B-type natriuretic peptide in differentiating congestive heart failure from lung disease in pediatric patients with respiratory distress. Pediatr Cardiol 25 (2004) 341-346
54. An JD Zhang Y.P., and Zhou J.H. Levels of serum brain natriuretic peptide in children with congestive heart failure or with severe pneumonia. Zhongguo Dang Dai Er Ke Za Zhi 8 (2006) 201-204
55. Holmgren D., Westerlind A., Lundberg P.A., and Wahlander H. Increased plasma levels of natriuretic peptide type B and A in children with congenital heart defects with left compared with right ventricular volume overload or pressure overload. Clin Physiol Funct Imaging 25 (2005) 263-269
56. Koch A., Zink S., and Singer H. B-type natriuretic peptide in paediatric patients with congenital heart disease. Eur Heart J 27 (2006) 861-866
57. Lin N.C., Landt M.L., Trinkaus K.M., Balzer D.T., Kort H.W., and Canter C.E. Relation of age, severity of illness, and hemodynamics with brain natriuretic peptide levels in patients < 20 years of age with heart disease. Am J Cardiol 96 (2005) 847-850
58. Suda K., Matsumura M., and Matsumoto M. Clinical implication of plasma natriuretic peptides in children with ventricular septal defect. Pediatr Int 45 (2003) 249-254
59. Puddy V.F., Amirmansur C., William A.F., and Singer D.R. Plasma brain natriuretic peptide as a predictor of haemodynamically significant patent ductus arteriosus in preterm infants. Clin Sci 103 (2002) 75-77
60. Sanjeev S., Pettersen M., Lua J., Thomas R., Shankaran S., and L'Ecuyer T. Role of plasma B-type natriuretic peptide in screening for hemodynamically significant patent ductus arteriosus in preterm neonates. J Perinatol 25 (2005) 709-713
61. Choi B.M., Lee K.H., Eun B.L., Yoo K.H., Hong Y.S., Son C.S., and Lee J.W. Utility of rapid B-type natriuretic peptide assay for diagnosis of symptomatic patent ductus arteriosus in preterm infants. Pediatrics 115 (2005) 255-261
62. Flynn P.A., da Graca R.L., Auld P.A., Nesin M., and Kleinman C.S. The use of a bedside assay for plasma B-type natriuretic peptide as a biomarker in the management of patent ductus arteriosus in premature neonates. J Pediatr 147 (2005) 38-42
63. Holmstrom H., Hall C., and Thaulow E. Plasma levels of natriuretic peptides and haemodynamic assessment of patent ductus arteriosus in preterm infants. Acta Paediatr 90 (2001) 184-191
64. Eerola A., Jokinen E., Boldt T., and Pihkala J. The influence of percutaneous closure of patent ductus arteriosus on left ventricular size and function: a prospective study using two- and three-dimensional echocardiography and measurements of serum natriuretic peptides. J Am Coll Cardiol 47 (2006) 1060-1066
65. Nagaya N., Nishikimi T., Uematsu M., Kyotani S., Satoh T., Nakanishi N., et al. Secretion patterns of brain natriuretic peptide and atrial natriuretic peptide in patients with or without pulmonary hypertension complicating atrial septal defects. Am Heart J 136 (1998) 297-301
66. Weber M., Dill T., Deetjen A., Neumann T., Evinci O., Hansel J., Elsaesser A., Mitrovic V., and Hamm C. Left ventricular adaptation after atrial septal defect closure assessed by increased concentrations of N-terminal pro-brain natriuretic peptide and cardiac magnetic resonance imaging in adult patients. Heart 92 (2006) 671-675
67. Muta H., Ishii M., Maeno Y., Akagi T., and Kato H. Quantitative evaluation of the changes in plasma concentrations of cardiac natriuretic peptide before and after transcatheter closure of atrial septal defect. Acta Paediatr 91 (2002) 649-652
68. Hayabuchi Y., Matsuaka S., and Kuroda Y. Plasma concentrations of atrial and brain natriuretic peptides and cyclic guanosine monophosphate in response to dobutamine infusion in patients with surgically repaired tetralogy of Fallot. Pediatr Cardiol 20 (1999) 343-350
69. Dodge-Khatami A., Buchel E.V., Knirsch W., Kadner A., Rousson V., Dave H.H., et al. Brain natriuretic peptide and magnetic resonance imaging in tetralogy with right ventricular dilatation. Ann Thorac Surg 82 (2006) 983-988
70. Ishii H., Harada K., Toyono M., Tamura M., and Takada G. Usefulness of exercise-induces changes in plasma levels of brain natriuretic peptide in predicting right ventricular contractile reserve after repair of tetralogy of Fallot. Am J Cardiol 95 (2005) 1338-1343
71. Mir T.S., Falkenberg J., Friedrich B., Gottschalk U., Le T.P., Laer S., and Weil J. Levels of brain natriuretic peptide in children with right ventricular overload due to congenital cardiac disease. Cardiol Young 15 (2005) 396-401
72. Trojnarska O., Szyszka A., Gwizdala A., Siniawski A., Oko-Sarnowska Z., and Chmara E. The BNP concentrations and exercise capacity assessment with cardiopulmonary stress test in patients after surgical repair of Fallot's tetralogy. Int J Cardiol 110 (2006) 86-92
73. Cowley C.G., Bradley J.D., and Shaddy R.E. B-type natriuretic peptide levels in congenital heart disease. Pediatr Cardiol 25 (2004) 336-340
74. Oosterhof T., Tulevski I.I., Vliegen H.V., Spijkerboer A.M., and Mulder B.J. Effects of volume and/or pressure overload secondary to congenital heart disease (tetralogy of Fallot or pulmonary stenosis) on right ventricular function using cardiovascular magnetic resonance an B-type natriuretic peptide levels. Am J Cardiol 97 (2006) 1051-1055
75. Tulevski I.I., Groenink M., Van Der Wall F.F., Van Velduisen D.J., Boomsma F., and Stoker J. Increased brain and atrial natriuretic peptides in patients with chronic right ventricular overload: correlation between plasma neurohormones and right ventricular dysfunction. Heart 86 (2001) 27-30
76. Cheung E.W., Lam W.W., Chiu C.S., Chau A.K., Cheung S.C., and Cheung Y.F. Plasma brain natriuretic peptide levels, right ventricular volume overload and exercise capacity in adolescents after surgical repair of tetralogy of Fallot. Int J Cardiol 121 (2007) 155-162
77. Ikeda T., Matsuda K., Ito H., Shirakami G., Miyamato Y., Yoshimasa K., Nakao K., and Ban T. Plasma levels of brain and atrial natriuretic peptides elevated in proportion to left ventricular end-systolic wall stress in patients with aortic stenosis. Am Heart J 133 (1997) 307-314
78. Werber I.L., Stewart R.A., Legget M.E., West T.M., French R.L., Sutton T.M., Yandle T.G., French J.K., Richards A.M., and White H.D. Increased plasma natriuretic peptide levels reflect symptom onset in aortic stenosis. Circulation 107 (2003) 1884-1890
79. Weber M., Arnold R., Rau M., Maikowski C., Keil E., Mitrovic V., Brandt R., and Hamm C. N-terminal pro braintype natriuretic peptide (NT-proBNP) is a highly sensitive biochemical marker for surgical therapy in patients with aortic stenosis. Circulation 108 Suppl. 17 (2003) IV513
80. Prasad N., Bridges A.B., Lang C.C., Clarkson P.B.M., MacLeod C., Pringle T.H., Struthers A.D., and MacDonald T.M. Brain natriuretic peptide concentrations in patients with aortic stenosis. Am Heart J 133 (1997) 477-479
81. Koch A. Plasma levels of B-type natriuretic peptide in children and adolescents with aortic valve stenosis. Eur Heart J 26 (2005) 1688-1689
82. Nagaya N., Nishikimi T., Okano Y., Uematsu M., Satoh T., Kyotani S., et al. Plasma brain natriuretic peptide levels increase in proportion to the extend of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol 31 (1998) 202-208
83. Leuchte H.H., Holzapfel M., Baumgartner R.A., Ding I., Neurohr C., Vogeser M., et al. Clinical significance of brain natriruretic peptide in primary pulmonary hypertension. J Am Coll Cardiol (2004) 764-770
84. Nagaya N., Nishikimi T., Uematsu M., Satoh T., Kyotani S., Sakamaki F., et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 102 (2000) 865-870
85. Andreassen A.K., Wergeland R., Simonsen S., Gerran O., Guevara G., and Ueland T. N-terminal Pro-B-type natriuretic peptide as an indicator of disease severity in a heterogeneous group of patients with chronic precapillary pulmonary hypertension. Am J Cardiol 98 (2006) 525-529
86. Reynolds E.W., Ellington J.G., Vranicar M., and Bada H.S. Brain-type natriuretic peptide in the diagnosis and management of persistent pulmonary hypertension of the newborn. Pediatrics 114 (2004) 1297-1304
87. Law Y.M., Ettedgui J., Beerman L., Maisel A., and Tofovic S. Comparison of plasma B-type natriuretic peptide levels in single ventricle patients with systemic ventricle heart failure versus isolated cavopulmonary failure. Am J Cardiol 98 (2006) 520-524
88. Wahlander H., Westerlind A., Lindstedt G., Lundberg P.A., and Holmgren D. Increased levels of brain and atrial natriuretic peptides after the first palliative operation, but not after a bidirectional Glenn anastomosis, in children with functionally univentricular hearts. Cardiol Young 13 (2003) 268-274
89. Yoshimura N., Yamaguchi M., Oshima Y., Oka S., Ootaki Y., Hasegawa T., et al. Suppression of the secretion of atrial and brain natriuretic peptide after total cavopulmonary connection. J Thorac Cardiovasc Surg 120 (2000) 764-769
90. Sun L.S., Dominguez C., Mallavaram N.A., and Quaegebeur J.M. Dysfunction of atrial and B-type natriuretic peptides in congenital univentricular defects. J Thorac Cardiovasc Surg 129 (2005) 1104-1110
91. Ostrow A.M., Freeze H., and Rychik J. Protein-losing enteropathy after Fontan operation: investigations into possible pathophysiologic mechanisms. Ann Thorac Surg 82 (2006) 695-700
92. Larsson D.A., Meurling C.J., Holmqvist F., Waktare G.F., and Thilen U.J. The diagnostic and prognostic value of BNP in adults with a systemic morphologically right ventricle or Fontan Type circulation. Int J Cardiol 114 (2007) 345-351
93. Hjortdal V.E., Stenbog E.V., Ravn H.B., Emmertsen K., Jensen K.T., and Pedersen E.B. Neurohormonal activation late after cavopulmonary connection. Heart 83 (2000) 439-443
94. Wazni O.M., Martin D.O., Marrouche N.F., Latif A.A., Ziada K., Shaaraoui M., et al. Plasma B-type natriuretic peptide levels predict postoperative atrial fibrillation in patients undergoing cardiac surgery. Circulation 110 (2004) 124-127
95. Hutfless R., Kazanegra R., Madani M., Bhalla M.A., Tulua-Tata A., Chen A., et al. Utility of B-type natriuretic peptide in predicting postoperative complications and outcomes in patients undergoing heart surgery. J Am Coll Cardiol 43 (2004) 1873-1879
96. Bergler-Klein J., Klaar U., Heger M., Rosenhek R., Mundigler G., Gabriel H., et al. Natriuretic peptides predict symptom-free survival and postoperative outcome in severe aortic stenosis. Circulation 109 (2004) 2302-2308
97. Koch A., Kitzsteiner T., Zink S., Cesnjevar R., and Singer H. Impact of cardiac surgery on plasma levels of B-type natriuretic peptide in children with congenital heart disease. Intern J Cardiol 114 (2007) 339-344
98. Mir T.S., Haun C., Lilje C., Laer S., and Weil J. Utility of N-terminal brain natriuretic peptide plasma concentrations in comparison to lactate and troponin in children with congenital heart disease following open-heart surgery. Pediatr Cardiol 27 (2006) 209-216
99. Ationu A., Singer D.R., Smith A., Elliott M., Burch M., and Carter N.D. Studies of cardiopulmonary bypass in children: implications for the regulation of brain natriuretic peptide. Cardiovasc Res 27 (1993) 1538-1541
100. Costello J.M., Backer C.L., Checchia P.A., Mavroudis C., Seipelt R.G., and Goodman D.M. Alterations in the natriuretic hormone system related to cardiopulmonary bypass in infants with congestive heart failure. Pediatr Cardiol 25 (2004) 347-353
101. Lindblade C.L., Chun D.S., Darragh R.K., Caldwell R.L., Murphy D.J., and Schamberger M.S. Value of plasma B-type natriuretic peptide as a marker for rejection in pediatric heart transplant recipients. Am J Cardiol 95 (2005) 909-911
102. Lan Y.T., Chang R.K., Alejos J.C., Burch C., and Wetzel G.T. B-type natriuretic peptide in children after cardiac transplantation. J Heart Lung Transplant 23 (2004) 558-563
103. Hammerer-Lercher A., Mair J., Antretter H., Ruttmann E., Poelzl G., Laufer G., et al. B-type natriuretic peptide as a marker of allograft rejection after heart transplantation. J Heart Lung Transplant 24 (2005) 1444-1448
104. Claudius I., Lan Y.T., Chang R.K., Wetzel G.T., and Alejos J. Usefulness of B-type natriuretic peptide as a noninvasive screening tool for cardiac allograft pathology in pediatric heart transplant recipients. Am J Cardiol 92 (2003) 1368-1370
105. Ationu A., Burch M., Singer D., Littleton P., and Carter N. Cardiac transplantation affects ventricular expression of brain natriuretic peptide. Cardiovasc Res 27 (1993) 188-189
106. Ationu A., Sorensen K., Whitehead B., Singer D., Burch M., and Carter N.D. Ventricular expression of brain natriuretic peptide gene following orthotopic cardiac transplantation in children-a three year follow up. Cardiovasc Res. 27 (1993) 2135-2139
107. Aggarwal S., Pettersen M.D., Bhambhani K., Gurczynski J., Thomas R., and L'Ecuyer T. B-type natriuretic peptide as a marker for cardiac dysfunction in anthracycline-treated children. Pediatr Blood Cancer 49 (2007) 812-816
108. Suzuki T., Hayashi D., Yamazaki T., Mizuno T., Kanda Y., Komuro I., Kurabayashi M., Yamaoki K., Mitani K., Hirai H., Nagai R., and Yazaki Y. Elevated B-type natriuretic peptide after anthracycline administration. Am Heart J 136 (1998) 362-363
109. Okumura H., Iuchi K., Yoshida T., Nakamura S., Takeshima M., Takamatsu H., et al. Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity. Acta Haematol 104 (2000) 158-163
110. Nousiainen T., Vanninen E., Jantunen E., Puustinen J., Remes J., Rantala A., et al. Natriuretic peptides during the development of doxorubicin-induced left ventricular diastolic dysfunction. J Intern Med 251 (2002) 228-234
111. Hayakawa H., Komada Y., Hirayama M., Hori H., Ito M., and Sakurai M. Plasma levels of natriuretic peptides in relation to doxorubicin-induced cardiotoxicity and cardiac function in children with cancer. Med Pediatr Oncol 3 (2001) 4-9
112. Pinarli F.G., Oguz A., Tunaoglu F.S., Karadeniz C., Gokcora N., and Elbeg S. Late cardiac evaluation of children with solid tumors after anthracycline chemotherapy. Pediatr Blood Cancer 44 (2005) 370-377
113. Germanakis I., Kalmanti M., Parthenakis F., Nikitovic D., Stiakaki E., and Patrianakos A. Correlation of plasma N-terminal pro-brain natriuretic peptide levels with left ventricle mass in children treated with anthracyclines. Int J Cardiol 108 (2006) 212-215
114. Sandri M.T., Salvatici M., Cardinale D., Zorzino L., Passerini R., Lentati P., et al. N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction?. Clin Chem 51 (2005) 1405-1410
115. Cardinale D., Colombo A., Sandri M.T., Lamantia G., Colombo N., Civelli M., et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 114 (2006) 2474-2481
116. Maeder M., Fehr T., Rickli H., and Ammann P. Sepsis-associated myocardial dysfunction: diagnostic and prognostic impact of cardiac troponins and natriuretic peptides. Chest 129 (2006) 1349-1366
117. Castillo J.R., Zagler A., Carrillo-Jimenez R., and Hennekens C.H. Brain natriuretic peptide: a potential marker for mortality in septic shock. Int J Infect Dis 8 (2004) 271-274
118. Palladini G., Campana C., Klersy C., Balduini A., Vadacca G., Perfetti V., Perlini S., Obici L., Ascari E., d'Eril G.M., Moratti R., and Merlini G. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 107 (2003) 2440-2445
119. Yasutake H., Seino Y., Kashiwagi M., Honma H., Matsuzaki T., and Takano T. Detection of cardiac sarcoidosis using cardiac markers and myocardial integrated backscatter. Int J Cardiol 102 (2005) 259-268
120. Kawamura T., Wago M., Kawaguchi H., Tahara M., and Yuge M. Plasma brain natriuretic peptide concentrations in patients with Kawasaki disease. Pediatr Int 42 (2000) 241-248
121. Freeman A.F., and Shulman S.T. Kawasaki disease: summary of the American Heart Association guidelines. Am Fam Physician 74 (2006) 1141-1148
122. Zhang Q.Y., Du J.B., Chen Y.H., and Li W.Z. Change in plasma N-terminal pro-brain natriuretic peptide in children with Kawasaki disease and its value in clinical practice. Zhonghua Er Ke Za Zhi 44 (2006) 886-890
123. Kurotobi S., Kawakami N., Shimizu K., Aoki H., Nasuno S., and Takahashi K. Brain natriuretic peptide as a hormonal marker of ventricular diastolic dysfunction in children with Kawasaki disease. Pediatr Cardiol 26 (2005) 425-430
124. Kawamura T., and Wago M. Brain natriuretic peptide can be useful biochemical marker for myocarditis in patients with Kawasaki disease. Cardiol Young 12 (2002) 153-158
125. Nir A., and Nasser N. Clinical value of NT-proBNP and BNP in pediatric cardiology. J Cardiac Fail 11 (2005) 876-880
126. Clerico A., and Emdin M. Natriuretic peptides: the hormones of the heart (2006), Springer -Verlag, Milan 1-184